CCM
BBIO icon

CAAS Capital Management’s BridgeBio Pharma BBIO Stock Holding History

CAAS Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$297K Buy
+8,600
New +$290K 0.03% 325
2020
Q3 		– Sell
-211,293
Closed -$6.89M – 480
2020
Q2 		$6.89M Buy
+211,293
New +$6.44M 0.23% 102

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

CAAS Capital Management's BBIO Position: Q1 2025 in Review

CAAS Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2025: 8,600 shares worth $297K. The stake represents 0.03% of the portfolio and ranks #325 among its holdings. This is a return to the name: CAAS Capital Management previously reported a position in BBIO as recently as Q2 2020.

CAAS Capital Management first reported a position in BBIO in Q2 2020 and has held it in 2 quarters since. The position peaked at $6.89M in Q2 2020. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

  • CAAS Capital Management held 8,600 shares of BridgeBio Pharma worth $297K as of Q1 2025.
  • BridgeBio Pharma was a new CAAS Capital Management position in Q1 2025.
  • BridgeBio Pharma made up 0.03% of CAAS Capital Management's portfolio in Q1 2025, its #325 holding.
  • CAAS Capital Management first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 2 quarters since.
  • CAAS Capital Management's BridgeBio Pharma position peaked at $6.89M in Q2 2020.
  • 304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.